Your browser doesn't support javascript.
loading
A Large Case-Control Study Performed in Spanish Population Suggests That RECQL5 Is the Only RECQ Helicase Involved in Breast Cancer Susceptibility.
Marchena-Perea, Erik Michel; Salazar-Hidalgo, Milton Eduardo; Gómez-Sanz, Alicia; Arranz-Ledo, Mónica; Barroso, Alicia; Fernández, Victoria; Tejera-Pérez, Hugo; Pita, Guillermo; Núñez-Torres, Rocío; Pombo, Luz; Morales-Chamorro, Rafael; Cano-Cano, Juana María; Soriano, Maria Del Carmen; Garre, Pilar; Durán, Mercedes; Currás-Freixes, María; de la Hoya, Miguel; Osorio, Ana.
Afiliación
  • Marchena-Perea EM; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Salazar-Hidalgo ME; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Gómez-Sanz A; Molecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.
  • Arranz-Ledo M; Cancer Genetics Group, Unidad de Excelencia Instituto de Biología y Genética Molecular, Universidad de Valladolid-Consejo Superior de Investigaciones Científicas (IBGM, UVa-CSIC), 47003 Valladolid, Spain.
  • Barroso A; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Fernández V; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Tejera-Pérez H; Human Cancer Genetics Programme, Human Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Pita G; Human Cancer Genetics Programme, Human Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Núñez-Torres R; Human Cancer Genetics Programme, Human Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • Pombo L; Medical Oncology Section, Universitary Hospital Complex of Albacete, 02006 Albacete, Spain.
  • Morales-Chamorro R; Medical Oncology Section, Hospitalary Compex La Mancha Centro, 13600 Alcázar de San Juan, Spain.
  • Cano-Cano JM; Medical Oncology Service, Universitary General Hospital of Ciudad Real, 13005 Ciudad Real, Spain.
  • Soriano MDC; Oncology Service, Virgen de la Luz Hospital, 16002 Cuenca, Spain.
  • Garre P; Molecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.
  • Durán M; Cancer Genetics Group, Unidad de Excelencia Instituto de Biología y Genética Molecular, Universidad de Valladolid-Consejo Superior de Investigaciones Científicas (IBGM, UVa-CSIC), 47003 Valladolid, Spain.
  • Currás-Freixes M; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
  • de la Hoya M; Molecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.
  • Osorio A; Human Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Cancers (Basel) ; 14(19)2022 Sep 28.
Article en En | MEDLINE | ID: mdl-36230663
Around 50% of the familial breast cancer (BC) cases are estimated to be caused by germline variants in known low-, moderate-, and high-risk susceptibility genes, while the other half is of unknown genetic origin. In the present study, we wanted to evaluate the role of the RECQ helicases, some of which have been studied in the past as candidates, with unclear results about their role in the disease. Using next-generation sequencing (NGS) technology, we analyzed the whole coding sequence of BLM, RECQL1, RECQL4, RECQL5, and WRN in almost 2000 index cases from BC Spanish families that had previously tested negative for the known BC susceptibility genes (BRCAX) and compared the results with the controls extracted from gnomAD. Our results suggest that BLM, RECQL1, RECQL4, and WRN do not play a major role in BC susceptibility. However, in the combined analysis, joining the present results with those previously reported in a series of 1334 BC Spanish patients and controls, we found a statistically significant association between Loss of Function (LoF) variants in RECQL5 and BC risk, with an OR of 2.56 (p = 0.009; 95% CI, 1.18-4.98). Our findings support our previous work and places the RECQL5 gene as a new moderate-risk BC gene.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: España